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BACKGROUND: Although gene expression profile of multiple myeloma (MM) patients shows a wide range of Bik/Nbk expression, varying
from absent to high, its regulation and function in myeloma cells is poorly understood. Thus, we addressed these questions in MM.
METHODS: Human myeloma cell lines (HMCLs) and primary purified myeloma cells were studied for Bcl-2 family protein expression by
western blot and further correlation analysis was performed. Correlative study between Bik and thyrotroph embryonic factor (TEF)
transcription factor expression was analysed by PCR. Stress oxidative response was analysed by flow cytometry.
RESULTS: A strong expression of Bik protein was found only in one out of three of HMCL and correlated to Bcl-2 expression (P¼0.0006).
We demonstrated that Bik could be regulated at the protein level by Bcl-2 and at the transcriptional level by TEF. Bik overexpression
sensitises myeloma cells to oxidative stress whereas Bik silencing increases resistance to H2O2 oxidative stress. Furthermore, Bik ectopic
expression disrupts Bim/Bcl-2 and Bim/Bcl-xL endogenous complexes triggering Bim release that could induce Bax and Bak activation.
CONCLUSIONS: Ours results suggest that Bik has a role in both, apoptosis induction and sensitivity to oxidative stress in myeloma cells. Small
BH3 mimetic molecules should be considered for further apoptosis-based therapy in myeloma cells expressing endogenous Bik/Bcl-2
complexes.
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Multiple myeloma (MM) is a plasma cell malignancy presently
incurable. It has a high degree of heterogeneity at presentation and
a great variability with regard to the clinical outcome of patients in
response to chemotherapy. Analyses of the global expression
profile of patients have lead to the molecular classification of MM
patients in different disease subtypes (Zhan et al, 2006). Recently,
new therapy, such as proteasome inhibitors or immunomodula-
tory drugs have been introduced into MM treatment showing
efficiency even in patients resistant to conventional chemotherapy
(Ocio et al, 2008). However, despite these advances in MM
treatment, all patients develop resistance to treatment that is often
characterized by a reduced apoptosis rate. Thus, a better under-
standing of how a cell evades apoptosis is needed. Members of the
Bcl-2 family are critical regulators of apoptosis and their ratio
between pro-survival and pro-apoptotic members mainly deter-
mines the fate of a cell following an apoptotic stimulus. Pro-
apoptotic BH3-only proteins are the most apical mediators of cell
death and their pro-apoptotic activity is tightly regulated by
diverse transcriptional and post-transcriptional mechanisms
(Puthalakath and Strasser, 2002). BH3-only proteins can be
subdivided in two groups, the sensitisers including Bmf, Bik/
Nbk, Bad, Noxa and the activators Bim, Bid and Puma (Letai et al,
2002). Whereas activator BH3-only proteins can directly activate
Bax or Bak, the role of sensitisers is to bind and occupy the
antiapoptotic Bcl-2 proteins. As the gene expression profile of MM
patients has demonstrated a wide range of Bik/Nbk expression,
from absent to very high (Zhan et al, 2003), we addressed the
regulation and the role of Bik in MM. Bik has been identified as a
binding partner and antagonist of pro-survival Bcl-xL and Bcl-2
and of two viral survival proteins, EBV-BHFR1 and adenovirus
E1B-19kDa (Boyd et al, 1995). Its BH3 domain is responsible of
the cell death-promoting activity and of physical interactions with
antiapoptotic molecules (Gillissen et al, 2003). Depending of the
cellular context, Bik can be either strongly apoptotic when
transfected in various cell lines (Han et al, 1996) or can sensitise
tumour cells to apoptosis mediated by chemotherapeutic agents or
by Fas (Daniel et al, 1999). Tight control of Bik gene expression at
multiple steps is probably essential, given the fact that Bik
harbours an already exposed BH3 domain (McDonnell et al, 1999).
It has been proposed that induction of Bik by genotoxic stress is
regulated at transcriptional level in a p53-dependent manner
(Mathai et al, 2002). DNA methylation was also implicated in Bik
transcriptional regulation (Sturm et al, 2006). More recently, it was
shown that PAR bZIP proteins, a family of transcription factors,
were able to regulate some BH3-only proteins (Ritchie et al, 2009).
More specifically, one of these transcription factors, thyrotroph
embryonic factor (TEF) directly controls Bik transcription. Indeed,
chromatin immunoprecipitation assays indicate that TEF protein
directly activates Bik promoter (Ritchie et al, 2009). In addition,
the implication of Bik in the development of human breast and
colorectal cancer was suggested because of the identification of a
region deletion on chromosome 22q13, where Bik gene is located
(Castells et al, 2000). Finally, post-transcriptional modifications
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swere also implicated in Bik regulation. Thus, Bik activity can be
regulated by phosphorylation which increases Bik pro-apoptotic
capacity, probably by enhancing its binding affinity with
antiapoptotic proteins Bcl-xL and Bcl-2 (Li et al, 2003).
In this study, we first confirmed that Bik expression in human
myeloma cells is very heterogeneous, varying from absent to very
high and we next addressed the question of Bik regulation of
expression and function in MM.
MATERIALS AND METHODS
Cells and culture conditions
KMS-11, KMM-1, KMS-12BM and KMS-12PE were kindly
provided by Dr T Otsuki (Okayama, Japan), JJN-3 by Dr Van Riet
(Belgium), JIM3 by Dr MacLennan (Birmingham, UK), Karpas 620
by Dr Karpas (Cambrigde, UK) and MM.1S by Dr Rosen
(Chicago, IL, USA). LP-1, L363, NCI-H929 and OPM-2 human
myeloma cell line (HMCL) were purchased from DSMZ (Braunsch-
weig, Germany) and U266 from the ATCC (Rockville, MA, USA).
The XG-1, XG-2, XG-5, XG-6, XG-7, NAN-1, NAN-3, NAN-6,
SBN and BCN HMCL have been previously established in our
laboratory from peripheral blood samples or pleural effusion
of patients with MM and are cultured in the presence of 3ngml
 1
of r–IL-6 (Novartis, Basel, Switzerland) (Bataille et al, 2006). Cell
lines were maintained in RPMI-1640 medium supplemented with
5% fetal calf serum, 2mM glutamine, antibiotics and 5 10
 5M
2–bME. Gradient density centrifugation using ficoll hypaque and
purification by CD138-immunomagnetic beads were used to
obtain purified malignant plasma cells from MM bone marrow
specimens after written informed consent given at the University
Hospital of Nantes. The purity of plasma cell population was
always superior to 90% as assessed by morphology.
Transient transfections and RNA interference assays
Transfection of KMM-1 was performed using Lipofectamin 2000
(Invitrogen Corp., Carlsbad, CA, USA). NCI-H929 and U266
HMCL were transfected using Amaxa Nucleofector (T solution,
X01 programme and R solution, T01 programme, respectively).
pcDNA3 Bik-HA and pRcCMV Bcl-2 were kindly provided by
Dr G Chinnadurai, USA and by Dr F Vallette, France, respectively.
Cells were transfected with 100pmol siRNA using Lipofectamine
2000. All siRNA oligos used, namely, Bik (L-004388-00-0005), Bcl-2
(L-003307-00-0005), TEF (L-008769-00-0005), Bax (L-003308-01-
0005) and Bak (L-009905-00-0005) were ON-TARGET plus siRNA
pools of four oligos targeting four different mRNA regions at once
and purchased from Dharmacon (Chicago, IL, USA).
Antibodies (mAbs) and reagents
Anti-Bcl-2 (clone 124) mouse mAb was obtained from Dako
(Roissy, CDG, France). Antibodies against caspase-3 (clone E-8)
mouse mAb, Bik (N-19) goat polyclonal, caspase-9 (clone F-7)
mouse mAb and Mcl-1 (S19) rabbit polyclonal were obtained from
Santa Cruz Biotechnology (Tebu-Bio, Le Perray en Yvelines,
France). Antibodies against PUMA rabbit polyclonal was from
Calbiochem (Merck, Darmstadt, Germany). Anti-Actin (clone C4)
and anti-Bim rabbit polyclonal antibodies were obtained from
Chemicon (Temecula, CA USA). Anti-Noxa (clone 114C307.1)
from Alexis (Coger, Paris, France).
Apoptotic cell death
Cell death was assessed by Apo 2.7 (Beckman Coulter, Marseille,
France) staining. Flow cytometry analysis was performed on a
FACSCalibur using the Cell Quest software (Becton Dickinson, San
Jose, CA, USA).
Immunoblotting
Cells (5 10
6) were resuspended in 150ml lysis buffer (10mM Tris,
pH 7.6, 150mM NaCl, 5mM EDTA and 1% Triton-X 100)
containing 2mM PMSF and 2mgml
 1 aprotinin. After 40min on
ice, lysates were cleared by centrifugation at 12000g for 30min at
41C. Equal amounts of total protein were separated by SDS–
PAGE, electrotransferred onto PVDF membranes and analysed
following standard procedures. The signal was detected by ECL
detection (Pierce, Rockford, IL, USA).
Immunoprecipitation
Cells (25 10
6) were lysed in 1% digitonin containing lysis
buffer. Whole-cell lysates were obtained, pre-cleared with protein
A-sepharose and then incubated overnight with 5mg of the specific
antibody. Immunocomplexes were captured with either protein
A-sepharose or protein G-agarose. Beads were pelleted, washed
three times and boiled in SDS sample buffer. The presence of
immune complexes was determined by western blotting analysis.
RT–PCR and sequencing
Total RNA was prepared using Nucleospin RNA II (Macherey-
Nagel Corporation, Du ¨ren, Germany). For complementary DNA
synthesis, 2mg of the total RNA was reverse transcribed using
the Moloney murine leukemia virus reverse transcriptase (Invitro-
gen Corp.,) and oligo-(dT)12-18 (Invitrogen). Amplification of
TEF, Bik and Actin was performed using the following primers:
TEF forward (50-TGGTCCTGAAGAAGCTGATGG-30) and reverse
(50-TCCAGGTCCATGTACTCCAG-30), Bik forward (50-GACCATG
GAGGTTCTTGGCA-30) and reverse (50- AGGCTCACGTCCATCTC
GTC-30) and Actin forward (50-ATCTGGCACCACACCTTCTAC
AATGAGCTGCG-30) and reverse (50-CGTCATACTCCTGCTTGCT
GATCCACATCTGC-30). P53 mutations were identified by direct
sequencing of RT–PCR products. For p53, two overlapping
amplifications, a 750pb (codons 1–250) and a 819pb (codons
187–370) products, were performed using the following primer
pairs: ATGGAGGAGCCGCAGTCA and GGCCTCCGGTTCATGC
CG (1–250), GGCCCCTCCTCAGCATCTT and TCCCCATCCTCCT
CCCCA (187–370).
Detection of ROS generation For ROS generation analysis, cells
were exposed to 200mM H2O2 during 2h and then incubated with
5mM dihydroethidine (DHE) (Molecular Probes, Eugene, OR, USA)
at 371C for 15min. After incubation, cells were washed twice with
ice-cold phosphate-buffered saline. Oxidation of DHE to oxyethi-
dium was then determined by flow cytometry.
RESULTS
Bik expression appears to be correlated to Bcl-2 expression
and lack of Bik expression is not related to lack of other
BH3-only protein
We used a fairly large number of HMCL (n¼24) to analyse Bik
expression. We found that only 9 HMCL (37.5%) displayed a
moderate to strong expression of Bik protein. In contrast, weak
expression or complete absence of Bik protein was observed in the
other HMCL (Figure 1A). We also analysed Bik expression in
CD138þ primary myeloma cells. Among 14 purified samples, Bik
protein levels were moderate to high in eight, and low to absent in
six primary myeloma samples. We, and others, have demonstrated
that pairs like Mcl-1/Bim and Bcl-2/Bim may mutually regulate
their expression (Jorgensen et al, 2007; Toumi-Wuille `me et al,
2007). In view of these findings, we were interested to establish
whether the absence or weak Bik expression detected in 62.5% of
HMCL was related to the expression of Bcl-2 or Bcl-xL. Western
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sblotting and further quantification analysis showed that Bik
expression was directly correlated to Bcl-2 protein expression
in both HMCL (Spearman’s r¼0.639 P¼0.0006) (Figure 1C)
and primary myeloma cells (Spearman’s r¼0.815 P¼0.0005).
However, no significant correlation was found between Bik and
Bcl-xL expression (Spearman’s r¼0.079 P¼0.711). Apart from
Bik, we analysed the expression of other BH3-only proteins, as loss
of Bik was previously shown to coincide with lack of Bim, Noxa
and Bad in renal cell carcinoma (Sturm et al, 2006). Most HMCL
expressed readily detectable levels of all three Bim isoforms EL,
L and S (76%). Bad was constitutive and homogeneously expres-
sed by all HMCL analysed (not shown). Despite of low or nega-
tive Noxa expression detected in around half of HMCL, no direct
correlation with Bik expression was observed (Figure 1A). Altogether,
these results suggest that in myeloma cells, Bik expression is directly
correlated to Bcl-2 levels whereas there is no relationship between Bik
expression and the expression of any other BH3-only protein studied.
Bcl-2/Bik complexes are involved in Bik protein stability
As BH3-only molecules are kept in check by the antiapoptotic
Bcl-2 proteins, we assessed the presence of constitutive Bik
complexes in XG-2 and KMS-12PE cells. Figure 2A shows that
myeloma cells displayed constitutive complexes of Bik essentially
with Bcl-2 rather than with Mcl-1. Taking into account the above
results, either the direct correlation between Bik/Bcl-2 expression
or the detection of endogenous Bik/Bcl-2 complexes, we assessed
the possible regulation effect of Bcl-2 expression on Bik levels.
Thus, overexpression of Bcl-2 in myeloma cells induced an accu-
mulation of Bik (Figure 2B). On the contrary, Bik overexpression
did not induce Bcl-2 accumulation (not shown). To confirm the
stabilisation of Bik by Bcl-2 in MM, we showed that down-
regulation of Bcl-2 by siRNA in U266 cells induced a decrease of
Bik expression (Figure 2C).
mRNA Bik expression correlates with the expression
of TEF mRNA independent of p53 status
Several transcription factors have been involved in the transcrip-
tion of Bik. More particularly, the tumour suppressor p53 was
implicated in the induction of Bik (Mathai et al, 2002). Therefore,
we compared the status of p53 of HMCL (Supplemental data)
with Bik expression showing no direct correlation between basal
expression of Bik protein and the status of p53 (Figure 3A). More
recently, it was demonstrated that TEF transcription factor directly
binds the promoter of Bik and controls its transcription. Thus, we
investigated the expression of TEF and Bik in our HMCL collection
by RT–PCR. Of interest, as shown in Figure 3A, the analysis of this
large collection of cell lines showed that Bik is expressed only in
the presence of TEF mRNA, except for XG2 cell line, indicating
that Bik gene could be transcriptionally activated by TEF in
myeloma cells. To validate this hypothesis, the effect of TEF
silencing on Bik expression was assessed (Figure 3B). In myeloma
cells, the downregulation of TEF mRNA triggers an important Bik
decrease, confirming the role of TEF in Bik transcription.
Bik is implicated in oxidative stress response
As it was demonstrated that TEF participates in oxidative stress
responses via Bik expression (Ritchie et al, 2009), we assessed the
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Figure 1 Bik expression is correlated with Bcl-2 expression. (A) Expression of BH3-only pro-apoptotic (Bik, Bim, Puma and Noxa) and antiapoptotic
(Bcl-2, Mcl-1, Bcl-xL) proteins on HMCL. Equivalent amounts of cell lysates (70mg of protein) were subjected to immunodetection with the indicated
antibodies. Protein loading was controlled by probing with an anti-actin antibody. (B) Expression of Bik and Bcl-2 proteins on purified primary myeloma cells.
(C) Bik and Bcl-2 from HMCL were quantified using Image-J software, both proteins were normalised by actin.
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srole of Bik in ROS generation. We transfected KMM-1 myeloma
cells with 0.5mg Bik complementary DNA leading to moderate Bik
ectopic expression that sensitises KMM-1 cells to oxidative stress,
as shown by the increase of oxyethidium formation (Figure 4A). In
agreement with this result, the silencing of Bik rendered U266
cells resistant to oxidative stress, as indicated by the decrease of
highly DHE-positive cells from 53 to 28% (Figure 4B). Altogether,
these results show the implication of Bik in H2O2 oxidative stress
responses in myeloma cells.
Transient ectopic expression of Bik induced cell death
To address the effect of ectopic expression of Bik, myeloma cells
were transiently transfected either with Bik or with an empty
vector. Ectopic Bik expression induced cell death detected by
Apo 2.7 staining and activation of both caspase-9 and caspase-3
(Figure 5A and B). To explore whether Bax or Bak was involved in
the pro-apoptotic function of Bik, silencing of Bak and Bax were
performed and resulted in a complete decrease of Bax and Bak
expression (Figure 5C). Knockdown of either Bak or Bax correlated
with a strong decrease of Bik induced apoptosis, 72 and 75%
respectively. These results indicate that overexpression of Bik
promotes cell apoptosis through a Bak /Bax-dependent mitochon-
drial pathway. To unravel the mechanism of Bik-induced cell
death, we analysed its binding partners under overexpression in
KMM1 cells by co-immunoprecipitation experiments. Although
ectopic Bik expression led to the formation of both Bcl-xL/Bik and
Bcl-2/Bik complexes, we observed a dissociation of Bcl-2/Bim and
Bcl-xL/Bim complexes as shown in Figure 5D. Thus, these findings
suggested that Bim is released from Bcl-xL and Bcl-2 and became
available to exert its pro-apoptotic function.
DISCUSSION
The importance of BH3-only pro-apoptotic proteins in cancer
therapy has become increasingly evident, and a wide variety of
transcriptional and post-translational mechanisms that regulate
their expression and activity has been reported (Puthalakath and
Strasser, 2002). In this report, we found that Bik levels are very
heterogeneous from absent to very high in both, cell lines and
primary myeloma cells. We first looked for a relationship between
Bik and other Bcl-2 family members. We provide evidence that
there is no relationship between the absence of Bik and the
presence of either Bim or Bad, as these two molecules are always
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Figure 2 Bcl-2 expression stabilises Bik protein. (A) Bik and Bcl-2 form
endogenous complexes in XG-2 and KMS-12PE HMCL. Lysates were
subjected to immunoprecipitations with anti-Bcl-2 or anti-Mcl-1 antibodies
and immunoblotting for the indicated proteins. (B) Ectopic expression of
Bcl-2 stabilises Bik protein. Cells were transfected with pRcCMV-Bcl-2 or
an empty vector. At 48h after transfection, cells were harversted. Extracts
were then immunoblotted for the indicated proteins. (C) Bcl-2 silencing
downregulates Bik expression. U266 cells were transfected with control or
Bcl-2 siRNA, protein expression was determined 24h after transfection.
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non-target control or TEF-specific siRNA. The mRNA levels were analysed by RT–PCR 72h after transfection.
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sexpressed in MM cells with the exception of Bim in one cell line.
Furthermore, while Noxa is absent in about 50% of HMCL, there is
no direct correlation between the lack of expression of Noxa and
Bik. The relationship of BH3-only proteins expression in myeloma
cells appears very different to the observation reported in renal cell
carcinoma, where loss of Bik coincides with lack of Bim, Noxa and
Bad (Sturm et al, 2006). Interestingly, we found that Bik expression
is directly correlated to Bcl-2 protein expression in both HMCL
(P¼0.0006) and primary myeloma cells (P¼0.0005). In contrast,
there is no significant correlation between Bik and Bcl-xL. We also
demonstrated that viable MM Bik-positive cells exhibit endogen-
ous abundant Bik/Bcl-2 complexes whereas no Mcl-1–Bik inter-
action was detected. We noticed that some cell lines expressing
very high levels of Bik and Bcl-2 harbour t(11;14) as U266,
KMS-12PE and Karpas 620. Interestingly, MM patients harbouring
this translocation do not belong to the worst prognosis group
(Avet-Loiseau et al, 2002). We, and others, have demonstrated that
some Bcl-2 family protein pairs may mutually regulate their
expression. Pairs like Mcl-1/Bim and Bcl-2/Bim support this
proposal (Jorgensen et al, 2007; Toumi-Wuille `me et al, 2007). In
view of these findings, we overexpressed Bcl-2, which induced an
important accumulation of Bik. Moreover, silencing of Bcl-2
triggers Bik downregulation, suggesting a direct effect of Bcl-2 on
Bik protein expression. According to this, Mathai et al demon-
strated in oral epithelial carcinoma cells that Bik expression was
directly influenced by the expression of Bcl-2 in an inducible
system. They suggested, using this model, that failure to observe
Bik induction in the absence of Bcl-2 may result from Bik
degradation (Mathai et al, 2002). Altogether, these results
suggested that a very high expression of Bik could be only the
reflection of an adaptation of the tumour to high Bcl-2 levels.
Besides the stabilisation of Bik by Bcl-2 at the protein level, it was
previously proposed that p53 indirectly influence Bik expression
(Mathai et al, 2002). We demonstrated that there is no direct
correlation between basal expression of Bik and the status of p53,
however we cannot rule out that Bik expression may be induced
once a genotoxic signal activates p53 in wild-type cell lines. More
recently, Ritchie et al demonstrated a transcriptional regulation of
Bik by TEF, a PARbZIP transcription factor, showing by both
promoter-reporter and chromatin immmunoprecipitation assays
that TEF protein activates directly Bik promoter (Ritchie et al,
2009). In agreement with this finding, we showed that Bik is
expressed only in the presence of TEF mRNA. Consistently, we
demonstrated that TEF silencing triggers a strong decrease of
Bik mRNA, confirming that Bik is transcriptionally activated by
TEF in myeloma cells. Finally, chromatin immmunoprecipitation
assays in MM cells confirmed that TEF protein activates directly
Bik promoter (result not shown). Despite TEF expression, some
cell lines do not express Bik, probably due to a potential deletion of
Bik at 22q13.2, as frequently described in other cancers (Sturm
et al, 2006). This hypothesis can be further sustained by the freq-
uent chromosomal abnormalities observed in MM (Magrangeas
et al, 2005). In addition, it was demonstrated that the PAR
bZIP pathway mediates oxidative stress-induced apoptosis via
Bik regulation. We consequently addressed the role of Bik in H2O2
oxidative stress response. Indeed, transient Bik expression
sensitises myeloma cells to oxidative stress whereas Bik silencing
increases resistance to this agent. Another study also demonstrates
the implication of Bik in oxidative stress induced by Bz-423 in B
cells, however other BH3-only proteins as Bad, Bim and Puma are
also implicated in this response (Blatt et al, 2009). In addition, we
found that ectopic expression of Bik in myeloma cells induces
apoptosis. This result is in agreement with previous data, showing
that ectopic expression of Bik results in apoptosis of a large
number of tumour cells as colon, prostate or melanoma (Gillissen
et al, 2003; Oppermann et al, 2005). Although ectopic expression of
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Figure 4 Bik contributes to the oxidative stress response. (A) Transient expression of Bik sensitises KMM-1 to oxidative stress. Cell line KMM-1 was
transiently transfected with Bik complementary DNA or an empty vector (control), after 48h, expression levels of Bik protein were determined by western
blot. Transfected cells were treated with 200mM H2O2 and then ROS generation was measured by dihydroethidine (DHE) staining followed by
fluorescence-activated cell sorting analysis. (B) Bik silencing promotes protection to oxidative stress. U266 were transfected with non-target control or
Bik-specific siRNA, 24h after transfection, lysates were obtained and analysed for Bik expression levels. Transfected cells were treated with 200mM H2O2
and stained as above. Results are representative of three independent experiments.
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sBik seems very effective to induce cell death, its dependence on
caspase activation is controversial (Gillissen et al, 2003, 2007;
Oppermann et al, 2005). We found that Bik-induced cell death in
myeloma cells is associated with caspase-9 and caspase-3 activation
suggesting that Bik promotes cell apoptosis through a mitochondrial–
associated caspase pathway in myeloma cells. Moreover, knockdown
of Bax or Bak showed that Bik induces cell death via a Bax/Bak-
dependent mechanism, indicating that Bax and Bak could have a
redundant role in this process. Furthermore, we provide evidence that
upon Bik overexpression, Bik is found associated with both Bcl-2 and
Bcl-xL and consequently triggers the disruption of Bim/Bcl-2 and Bim/
Bcl-xL endogenous complexes. These findings suggest that Bik ectopic
expression leads to Bim release that becomes available to exert its pro-
apoptotic function through Bax and Bak activation.
Finally, myeloma cells expressing high endogenous Bik/Bcl-2
complexes could exhibit a ‘deadly phenotype’, as previously
described for Bim/Bcl-2 pairs (Deng et al, 2007). Therefore, small
BH3 mimetic molecules should be taken into consideration for
further apoptosis-based therapy in myeloma cells that constitu-
tively express endogenous Bik/Bcl-2 complexes.
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